| DB ID | MyCo_2468 |
| Title | Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients |
| Year | 2009 |
| PMID | 19117035 |
| Fungal Diseases involved | Pulmonary aspergillosis |
| Associated Medical Condition | Neutropenic Hematology Patients |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Belgium |
| Cohort | Seventy patients with proven (n= 27) or probable (n= 43) IPA fulfilled all entry criteria |
| Cohort No. | 70 |
| Age Group | 16-85 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive pulmonary aspergillosis (IPA) continues to be a cause of high morbidity, mortality, and resource utilization among patients with hematologic cancers.1 For many of these patients, it remains diffi- cult to secure the diagnosis of IPA.2 However, assessing aspergillosis outcome is equally problematic, both in daily clinical practice and in clinical studies. Specifically the absence of a sensitive surrogate marker to monitor treatment response leaves clinicians with insensitive, nonspecific, and very often conflicting pieces of information. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit- Platelia Aspergillus (Platelia Aspergillus EIA, Bio-Rad, France). |
| Assay Data | None |
| Validation Techniques used | FDA Approved -Platelia Aspergillus ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
